Introduction Injection-related adverse events (AEs) may occur with the use of any injectable substance, including all currently commercially available fillers. The most common of these AEs include discomfort, bruising, edema,…

INTRODUCTION There has been significant growth in both patient interest and physician use of soft tissue augmentation in recent years, especially among younger patients. Patients’ motivation behind this increased interest…

Introduction Poly-L-lactic acid (PLLA) was approved for use in Europe in 1999. In the United States, it was approved by the Food and Drug Administration in 2004 for the treatment…

It brings me great pleasure to introduce this edition of the JDD highlighting articles on skin cancer. I’d like to take this opportunity to make it personal – and share…

Basal cell carcinoma (BCC) is the most common human cancer.1 When detected early the vast majority of cases are successfully managed surgically, with 5-year cure rates exceeding 90%.2 Although rare,…

I thoroughly enjoyed reading the two articles by Drs. Emanuele and Spencer in your March Issue. The first article, “From DNA repair to proteome protection: new molecular insights for preventing…

INTRODUCTION Histopathologic examination of preoperative biopsy specimens remains paramount in terms of diagnosing melanoma. Rates of diagnosing melanoma accurately from a purely clinical basis leave much to be desired, with…

INTRODUCTIONBiobrane (Smith & Nephew, London, UK) is a biosynthetic wound dressing that has been widely used in burn treatment and as a skin graft donor site dressing.1,2 It has been…

INTRODUCTION Systemic lupus erythematosus (SLE) is the second most common autoimmune disorder amongst women of childbearing age after thyroid disease. SLE is challenging to manage as it affects the body…

The Psoriasis Area Severity Index (PASI) is the most commonly utilized and extensively validated tool to assess the severity of psoriasis and treatment effect, especially in clinical research.1,2 PASI quantitatively…

INTRODUCTION Psoriasis, eczema and other immune-mediated skin diseases arise in the context of cutaneous inflammation.1 The majority of treatments for these conditions target the effector arm of the immune response,…